How are you interpreting the early RASolute 302 trial findings (daraxonrasib) in metastatic PDAC?

This is an extremely exciting time in pancreatic cancer treatment! I note that PDAC/KRAS has a plenary this year at ASCO's Annual Meeting. The company has also put out a press release stating this is a positive study against chemotherapy with a doubling of overall survival. Of course, we all want to...

I think the early RASolute 302 signal is very promising and could be practice-changing, but I would still interpret it with some caution until we see the full dataset.

The reported improvement in overall survival is striking—approximately 13.2 months vs 6.7 months with chemotherapy, essentially a do...

Obviously, we must see the data and await the ASCO presentation eagerly.

But after years of gemcitabine plus “your drug here” trials (since first approved in 1996 based on an invented clinical endpoint), and seeing all those drugs fail, and after years of only improvement through chemotherapy triple...

Second-line therapy for KRAS-mutant metastatic PDAC currently follows the same framework as for all-comers, as no KRAS G12D–targeted agents are yet FDA-approved or included in the guidelines for PDAC. For patients with good PS (ECOG 0–1) after prior gemcitabine-based therapy, fluorouracil/leucovorin...